RARE
Ultragenyx Pharmaceutical Inc.
RARE
(1.0)57,70 USD
-61.3% ROA
-369.54% ROE
-5.24x PER
3.815.856.168,00 USD
38.05% DER
0% Yield
-139.7% NPM
Ultragenyx Pharmaceutical Inc. Stock Analysis
Ultragenyx Pharmaceutical Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a low debt to equity ratio (38%), which means it has a small amount of debt compared to the ownership it holds |
|
| 2 |
Revenue Growth
With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity. |
|
| 3 |
ROE
Negative ROE (-346.34%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity. |
|
| 4 |
ROA
The stock's ROA (-61.3%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns. |
|
| 5 |
PBV
The stock's high Price-to-Book Value (P/BV) ratio (90.32x) suggests it's overvalued, potentially making it an expensive investment. |
|
| 6 |
Net Profit Growth
This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option. |
|
| 7 |
Assets Growth
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option. |
|
| 8 |
Graham Number
The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity. |
|
| 9 |
Dividend Growth
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns. |
|
| 10 |
Dividend
No dividends from the company in the past three years raises doubts about its profitability for shareholders. |
|
| 11 |
Buffet Intrinsic Value
The company's stock shows signs of being overvalued (-32) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value. |
Ultragenyx Pharmaceutical Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Buy |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Ultragenyx Pharmaceutical Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2011 | 0 | |
| 2012 | 0 | 0% |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 133.000 | 100% |
| 2017 | 2.612.000 | 94.91% |
| 2018 | 51.495.000 | 94.93% |
| 2019 | 103.714.000 | 50.35% |
| 2020 | 271.030.000 | 61.73% |
| 2021 | 351.406.000 | 22.87% |
| 2022 | 363.329.000 | 3.28% |
| 2023 | 392.208.000 | 7.36% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2011 | 4.717.000 | |
| 2012 | 12.641.000 | 62.68% |
| 2013 | 27.829.000 | 54.58% |
| 2014 | 45.967.000 | 39.46% |
| 2015 | 114.737.000 | 59.94% |
| 2016 | 183.204.000 | 37.37% |
| 2017 | 231.644.000 | 20.91% |
| 2018 | 293.998.000 | 21.21% |
| 2019 | 357.355.000 | 17.73% |
| 2020 | 412.084.000 | 13.28% |
| 2021 | 497.153.000 | 17.11% |
| 2022 | 705.789.000 | 29.56% |
| 2023 | 628.980.000 | -12.21% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2011 | 1.844.000 | |
| 2012 | 3.344.000 | 44.86% |
| 2013 | 4.451.000 | 24.87% |
| 2014 | 10.811.000 | 58.83% |
| 2015 | 33.001.000 | 67.24% |
| 2016 | 64.936.000 | 49.18% |
| 2017 | 99.909.000 | 35% |
| 2018 | 127.724.000 | 21.78% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2011 | -6.545.000 | |
| 2012 | -16.021.000 | 59.15% |
| 2013 | -34.626.000 | 53.73% |
| 2014 | -56.778.000 | 39.02% |
| 2015 | -146.354.000 | 61.21% |
| 2016 | -248.007.000 | 40.99% |
| 2017 | -328.942.000 | 24.6% |
| 2018 | -541.695.000 | 39.28% |
| 2019 | -411.722.000 | -31.57% |
| 2020 | -322.471.000 | -27.68% |
| 2021 | -381.496.000 | 15.47% |
| 2022 | -639.411.000 | 40.34% |
| 2023 | -559.660.000 | -14.25% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2011 | 0 | |
| 2012 | 0 | 0% |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 133.000 | 100% |
| 2017 | 2.611.000 | 94.91% |
| 2018 | 50.349.000 | 94.81% |
| 2019 | 94.706.000 | 46.84% |
| 2020 | 264.901.000 | 64.25% |
| 2021 | 335.398.000 | 21.02% |
| 2022 | 335.009.000 | -0.12% |
| 2023 | 348.260.000 | 3.8% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2011 | -6.849.000 | |
| 2012 | -16.334.000 | 58.07% |
| 2013 | -35.070.000 | 53.42% |
| 2014 | -59.802.000 | 41.36% |
| 2015 | -145.618.000 | 58.93% |
| 2016 | -245.874.000 | 40.78% |
| 2017 | -302.139.000 | 18.62% |
| 2018 | -197.611.000 | -52.9% |
| 2019 | -402.727.000 | 50.93% |
| 2020 | -186.566.000 | -115.86% |
| 2021 | -454.025.000 | 58.91% |
| 2022 | -707.421.000 | 35.82% |
| 2023 | -638.596.000 | -10.78% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2011 | 0 | |
| 2012 | -1 | 0% |
| 2013 | -1 | 100% |
| 2014 | -2 | 50% |
| 2015 | -4 | 33.33% |
| 2016 | -6 | 50% |
| 2017 | -7 | 14.29% |
| 2018 | -4 | -133.33% |
| 2019 | -7 | 57.14% |
| 2020 | -3 | -133.33% |
| 2021 | -7 | 50% |
| 2022 | -10 | 40% |
| 2023 | -9 | -25% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2011 | -6.373.000 | |
| 2012 | -13.595.000 | 53.12% |
| 2013 | -31.607.000 | 56.99% |
| 2014 | -46.783.000 | 32.44% |
| 2015 | -110.932.000 | 57.83% |
| 2016 | -171.163.000 | 35.19% |
| 2017 | -256.636.000 | 33.31% |
| 2018 | -294.642.000 | 12.9% |
| 2019 | -370.215.000 | 20.41% |
| 2020 | -176.125.000 | -110.2% |
| 2021 | -411.788.000 | 57.23% |
| 2022 | -526.588.000 | 21.8% |
| 2023 | 34.877.000 | 1609.84% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2011 | -5.825.000 | |
| 2012 | -12.504.000 | 53.41% |
| 2013 | -31.200.000 | 59.92% |
| 2014 | -44.634.000 | 30.1% |
| 2015 | -105.977.000 | 57.88% |
| 2016 | -160.975.000 | 34.17% |
| 2017 | -253.843.000 | 36.58% |
| 2018 | -290.566.000 | 12.64% |
| 2019 | -345.383.000 | 15.87% |
| 2020 | -132.220.000 | -161.22% |
| 2021 | -338.695.000 | 60.96% |
| 2022 | -380.465.000 | 10.98% |
| 2023 | 34.877.000 | 1190.88% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2011 | 548.000 | |
| 2012 | 1.091.000 | 49.77% |
| 2013 | 407.000 | -168.06% |
| 2014 | 2.149.000 | 81.06% |
| 2015 | 4.955.000 | 56.63% |
| 2016 | 10.188.000 | 51.36% |
| 2017 | 2.793.000 | -264.77% |
| 2018 | 4.076.000 | 31.48% |
| 2019 | 24.832.000 | 83.59% |
| 2020 | 43.905.000 | 43.44% |
| 2021 | 73.093.000 | 39.93% |
| 2022 | 146.123.000 | 49.98% |
| 2023 | 0 | 0% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2011 | 10.643.000 | |
| 2012 | 84.340.000 | 87.38% |
| 2013 | 50.109.000 | -68.31% |
| 2014 | 184.945.000 | 72.91% |
| 2015 | 531.090.000 | 65.18% |
| 2016 | 473.974.000 | -12.05% |
| 2017 | 383.454.000 | -23.61% |
| 2018 | 608.908.000 | 37.03% |
| 2019 | 653.764.000 | 6.86% |
| 2020 | 1.154.375.000 | 43.37% |
| 2021 | 922.561.000 | -25.13% |
| 2022 | 352.494.000 | -161.72% |
| 2023 | 31.714.000 | -1011.48% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2011 | 12.129.000 | |
| 2012 | 88.316.000 | 86.27% |
| 2013 | 59.649.000 | -48.06% |
| 2014 | 197.967.000 | 69.87% |
| 2015 | 559.569.000 | 64.62% |
| 2016 | 540.626.000 | -3.5% |
| 2017 | 490.753.000 | -10.16% |
| 2018 | 719.558.000 | 31.8% |
| 2019 | 1.135.496.000 | 36.63% |
| 2020 | 1.759.555.000 | 35.47% |
| 2021 | 1.522.397.000 | -15.58% |
| 2022 | 1.545.444.000 | 1.49% |
| 2023 | 1.238.140.000 | -24.82% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2011 | 1.486.000 | |
| 2012 | 3.976.000 | 62.63% |
| 2013 | 9.540.000 | 58.32% |
| 2014 | 13.022.000 | 26.74% |
| 2015 | 28.479.000 | 54.28% |
| 2016 | 66.652.000 | 57.27% |
| 2017 | 107.299.000 | 37.88% |
| 2018 | 110.650.000 | 3.03% |
| 2019 | 481.732.000 | 77.03% |
| 2020 | 605.180.000 | 20.4% |
| 2021 | 599.836.000 | -0.89% |
| 2022 | 1.192.950.000 | 49.72% |
| 2023 | 1.206.426.000 | 1.12% |
Ultragenyx Pharmaceutical Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 5.72
- Net Income per Share
- -8.86
- Price to Earning Ratio
- -5.24x
- Price To Sales Ratio
- 9.3x
- POCF Ratio
- -10.14
- PFCF Ratio
- -9.61
- Price to Book Ratio
- 105.01
- EV to Sales
- 9.15
- EV Over EBITDA
- -6.64
- EV to Operating CashFlow
- -11.43
- EV to FreeCashFlow
- -9.46
- Earnings Yield
- -0.19
- FreeCashFlow Yield
- -0.1
- Market Cap
- 3,82 Bil.
- Enterprise Value
- 3,76 Bil.
- Graham Number
- 9.39
- Graham NetNet
- -9.61
Income Statement Metrics
- Net Income per Share
- -8.86
- Income Quality
- 0.69
- ROE
- -3.46
- Return On Assets
- -0.41
- Return On Capital Employed
- -0.47
- Net Income per EBT
- 1
- EBT Per Ebit
- 1.07
- Ebit per Revenue
- -1.31
- Effective Tax Rate
- 0
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 1.61
- Stock Based Compensation to Revenue
- 0.32
- Gross Profit Margin
- 0.9
- Operating Profit Margin
- -1.31
- Pretax Profit Margin
- -1.4
- Net Profit Margin
- -1.4
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -4.58
- Free CashFlow per Share
- -5.54
- Capex to Operating CashFlow
- 0.21
- Capex to Revenue
- -0.17
- Capex to Depreciation
- -4.4
- Return on Invested Capital
- -10.62
- Return on Tangible Assets
- -0.61
- Days Sales Outstanding
- 70.53
- Days Payables Outstanding
- 316.43
- Days of Inventory on Hand
- 301.68
- Receivables Turnover
- 5.18
- Payables Turnover
- 1.15
- Inventory Turnover
- 1.21
- Capex per Share
- -0.96
Balance Sheet
- Cash per Share
- 6,17
- Book Value per Share
- 0,44
- Tangible Book Value per Share
- -2.37
- Shareholders Equity per Share
- 0.44
- Interest Debt per Share
- 1.07
- Debt to Equity
- 0.38
- Debt to Assets
- 0.01
- Net Debt to EBITDA
- 0.11
- Current Ratio
- 2.06
- Tangible Asset Value
- -0,17 Bil.
- Net Current Asset Value
- -0,68 Bil.
- Invested Capital
- 0.38
- Working Capital
- 0,27 Bil.
- Intangibles to Total Assets
- 0.16
- Average Receivables
- 0,07 Bil.
- Average Payables
- 0,04 Bil.
- Average Inventory
- 30029000
- Debt to Market Cap
- 0
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Ultragenyx Pharmaceutical Inc. Profile
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
- CEO
- Dr. Emil D. Kakkis M.D., Ph.D.
- Employee
- 1.276
- Address
-
60 Leveroni Court
Novato, 94949
Ultragenyx Pharmaceutical Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Howard Horn Executive Vice President of Corporate Strategy & Chief Financial Officer |
70 |
| 2 |
Mr. Dennis Karl Huang Chief Technical Operations Off., Gene Therapy Research & Development and Executive Vice President |
70 |
| 3 |
Mr. Theodore A. Huizenga Senior Vice President, Corporate Controller & Principal Accounting Officer |
70 |
| 4 |
Ms. Karah Herdman Parschauer J.D. Chief Legal Officer & Executive Vice President of Corporate Affairs |
70 |
| 5 |
Mr. Erik Harris Executive Vice President & Chief Commercial Officer |
70 |
| 6 |
Ms. Danielle Keatley Senior Director of Investor Relations & Corporate Communications |
70 |
| 7 |
Mr. Ernie W. Meyer Chief Human Resources Officer & Executive Vice President |
70 |
| 8 |
Mr. Thomas R. Kassberg Chief Business Officer & Executive Vice President |
70 |
| 9 |
Mr. John Richard Pinion II Chief Quality Operations Officer & Executive Vice President of Translational Sciences |
70 |
| 10 |
Dr. Emil D. Kakkis M.D., Ph.D. Founder, President, Chief Executive Officer & Director |
70 |
Ultragenyx Pharmaceutical Inc. Competitors
